

**TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES**

**Patent number:** WO9800173  
**Publication date:** 1998-01-08  
**Inventor:** ZHAO ZHIYANG (US); TOMASSELLI ALFREDO G (US); KOEPLINGER KENNETH A (US); PETERSON TILLIE (US); SUARATO ANTONINO (IT)  
**Applicant:** UPJOHN CO (US); ZHAO ZHIYANG (US); TOMASSELLI ALFREDO G (US); KOEPLINGER KENNETH A (US); PETERSON TILLIE (US); SUARATO ANTONINO (IT)  
**Classification:**  
- **International:** **A61K47/48; A61K47/48;** (IPC1-7): A61K47/48  
- **European:** A61K47/48H4  
**Application number:** WO1997US10817 19970701  
**Priority number(s):** US19960022489P 19960703

**Also published as:**

WO9800173 (A)  
EP0909184 (A3)  
EP0909184 (A2)  
EP0909184 (B1)

**Cited documents:**

EP0391799  
US5294720  
WO9530670  
WO9411361  
WO8807378  
more >>

**Report a data error he****Abstract of WO9800173**

The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free -NH- which has been derivatized by the attachment of an electrophile containing a moiety such as p-CN- or p-NO<sub>2</sub>-pyridinylsulfonyl groups, or p-NO<sub>2</sub>- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The precursor is a synthetic intermediate carrying a free -NH- which has been derivatized by the attachment of an electrophile via a sulfonamide bond.

Data supplied from the **esp@cenet** database - Worldwide